益肾通络方对低中危特发性膜性肾病患者肾小管功能的影响  

Effect of Yishen Tongluo(益肾通络)Formula on Renal Tubular Function in Patients with Low-and Medium-risk Idiopathic Membranous Nephropathy

作　　者：毛竞宇 刘昊 辛鑫 陈素枝 赵美姣 檀淼[4] 杨凤文 檀金川[3] Mao Jingyu;Liu Hao;Xin Xin;Chen Suzhi;Zhao Meijiao;Tan Miao;Yang Fengwen;Tan Jinchuan(Hebei University of Chinese Medicine,Shijiazhuang 050200;Hebei Academy of Traditional Chinese Medicine,Shijiazhuang 050031;The First Affiliated Hospital of Hebei University of Chinese Medicine,Shijiazhuang 050011;The Fourth Hospital of Hebei Medical University,Shijiazhuang 050000)

机构地区：[1]河北中医学院,石家庄050200 [2]河北省中医药科学院,石家庄050031 [3]河北中医学院第一附属医院,石家庄050011 [4]河北医科大学第四医院,石家庄050000

出　　处：《中药药理与临床》2022年第2期202-206,共5页Pharmacology and Clinics of Chinese Materia Medica

基　　金：河北省自然科学基金资助项目(编号:2019423037);河北省中医药管理局资助项目(编号:2020072)

摘　　要：目的:观察益肾通络方对低中危特发性膜性肾病(IMN)患者的临床疗效及肾小管功能的影响。方法:本研究将60例低中危IMN患者依随机数字表法划分为对照组、观察组,每组30例,对照组给予西医基础治疗,观察组在上述疗法上加服益肾通络方。两组均治疗3个月,观察两组病人治疗前后的疗效、中医证候总积分、N-乙酰-β-D氨基葡萄糖糖苷酶(NAG)、尿α1-微球蛋白(α1-MG)、尿β2-微球蛋白(β2-MG)、尿Kim-1、尿NGAL、24 h尿蛋白定量(UTP)、白蛋白(ALB)、总胆固醇(TC)、三酰甘油(TG)、血肌酐(Scr)及安全性指标的变化。结果:观察组的临床有效率、中医证候总积分均明显优于对照组(P<0.05)。与治疗前相比,治疗后两组尿NAG、尿α1-MG、尿β2-MG、尿Kim-1、尿NGAL、UTP、TC、TG含量下降幅度明显(P<0.05);两组ALB明显升高(P<0.05);治疗后与对照组比较,观察组的尿NAG、尿α1-MG、尿β2-MG、尿Kim-1、尿NGAL、UTP、TC、TG含量均明显降低(P<0.05),观察组患者ALB含量明显升高(P<0.05)。结论:益肾通络方治疗低中危IMN,能有效改善临床症状,缓解肾小管损伤,进而保护肾脏,具有一定的临床推广价值。Objective:To observe the clinical effect of Yishen Tongluo Formula on renal tubular function of patients with low-and medium-risk idiopathic membranous nephropathy(IMN).Methods:Sixty patients with low and medium-risk IMN were divided into a control group and an observation group according to a random number table,with 30 cases in each group.The patients in the control group received conventional western medicine treatment,while those in the observation group received Yishen Tongluo Formula combined with western medicine.Both groups were treated for 3 months.The curative efficacies before and after treatment,total scores of traditional Chinese medicine(TCM)syndromes,N-acetyl-β-D glucosaminidase(NAG),urinaryα1-microglobulin(α1-MG),urinaryβ2-microglobulin(β2-MG),urinary Kim-1,urinary NGAL,24-hour urinary total protein(UTP),albumin(ALB),total cholesterol(TC),triglycerides(TG),serum creatinine(Scr),and changes in safety indicators of both groups were observed.Results:The clinical effective rate and the total score of TCM syndromes of the observation group were superior to those of the control group(P<0.05).Compared with the conditions before treatment,the levels of urinary NAG,urinaryα1-MG,urinaryβ2-MG,urinary Kim-1,urinary NGAL,UTP,TC,TG were reduced in both groups after treatment(P<0.05),while the ALB content increased(P<0.05).Compared with the control group after treatment,the observation group showed reduced content of urinary NAG,urinaryα1-MG,urinaryβ2-MG,urinary Kim-1,urinary NGAL,UTP,TC and TG(P<0.05),and increased ALB content(P<0.05).Conclusion:Yishen Tongluo Formula can effectively improve clinical symptoms,relieve renal tubular damage,and protect the kidney in the treatment of low-and medium-risk IMN,with certain clinical promotion value.

关 键 词：益肾通络方 低中危 特发性膜性肾病 肾小管功能 

分 类 号：R277.5[医药卫生—中医学]